| 林琳,陈健,刘虎,等.德曲妥珠单抗治疗转移性乳腺癌的效果及安全性[J].中国临床保健杂志,2024,27(3):406-409. |
| 德曲妥珠单抗治疗转移性乳腺癌的效果及安全性 |
| Efficacy and safety of trastuzumab deruxtecan in the treatment of metastatic breast cancer |
| 投稿时间：2024-05-16 |
| DOI：10.3969/J.issn.1672-6790.2024.03.028 |
| 中文关键词: 乳腺肿瘤 德曲妥珠单抗 HER-2 方案评价 药物相关性副作用和不良反应 |
| 英文关键词: Breast neoplasms Trastuzumab deruxtecan HER-2 Program evaluation Drug-related side effects and adverse reactions 〖FL |
| 基金项目:安徽省教育厅高校科研计划项目(2022AH010077) |
|
| 摘要点击次数: 932 |
| 全文下载次数: 543 |
| 中文摘要: |
| 目的 探讨德曲妥珠单抗二线及以上治疗晚期乳腺癌患者的有效性及安全性。方法 选取中国科学技术大学附属第一医院(安徽省立医院)肿瘤化疗科2023年3月至2024年3月收治的采用德曲妥珠单抗治疗的34例人表皮生长因子受体2(HER-2)阳性或低表达晚期乳腺癌患者的临床资料,回顾性分析患者的临床病理特征、客观缓解率、疾病控制率和不良反应发生情况。采用Fisher确切概率法比较组间差异。结果 共入组女性34例,中位年龄55.5岁；25例为HER-2阳性,9例为HER-2低表达；治疗线数为2~10线,中位4线,客观缓解率为35.29%(12/34),疾病控制率为58.82%(20/34)；其中三线以上及内脏危象的患者较早线和无内脏危象患者疾病控制率下降,差异有统计学意义(P＜0.05)。不良反应主要为恶心、乏力、天冬氨酸氨基转移酶升高及骨髓抑制等,其中3级以上不良反应主要为血液学毒性包括白细胞减少、粒细胞缺乏、血小板减少、淋巴细胞减少及腹泻,其余均为1或2级不良反应。结论 德曲妥珠单抗在晚期HER-2阳性或低表达乳腺癌中疗效确切,安全性较好,建议早期应用德曲妥珠单抗。 |
| 英文摘要: |
| Objective To explore the efficacy and safety of the second line and above of trastuzumab deruxtecan in the treatment of advanced breast cancer.Methods The study retrospectively analyzed the clinical data of 34 patients of metastatic breast cancer with HER-2-positive or HER-2-low who were treated with trastuzumab deruxtecan at the Department of Oncology,the First Affiliated Hospital of University of Science and Technology of China from March 2023 to March 2024.The analysis encompassed an evaluation of clinicopathological characteristics,objective response rate,disease control rate and incidence of adverse reactions of the patients.Statistical analysis was performed utilizing Fisher′s exact test.Results A total of 34 women were enrolled,with a median age of 55.5 years.Of these participants,25 patients were identified as HER-2-positive,while 9 patients exhibited low expression of HER-2.The number of treatment lines ranged from 2 to 8,with a median of 4 lines.The objective response rate was 35.29%(12/34),and the disease control rate was 58.82%(20/34).Notably,the disease control rate of patients with more than three lines and visceral crisis was significantly lower than that of patients with early line and no visceral crisis,and there was statistically significant(P＜0.05).The most common adverse reactions included nausea,fatigue,increased aspartate aminotransferase and myelosuppression.Grade 3 or higher adverse reactions were primarily hematological toxicities such as leukopenia,agranulocytosis,thrombocytopenia,lymphocytopenia and diarrhea,while the remaining reactions were of grade 1-2 severity.Conclusions Trastuzumab deruxtecan has shown both efficacy and safety in the treatment of metastatic breast cancer with HER-2 positive or low expression.Early initiation of trastuzumab deruxtecan is advised. |
|
查看全文
|
| 关闭 |
|
|
|